Altimmune NASDAQ: ALT executives outlined the company's strategy to build a liver-disease franchise

AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across

Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and low

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical

AbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Childre

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Europea

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

Altimmune (NASDAQ: ALT - Get Free Report) and Denali Therapeutics (NASDAQ: DNLI - Get Free Report) a

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics I

New York, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Alpha AI Corporation ("Alpha AI"), developer of the

Bank of America Corp DE boosted its position in shares of Altimmune, Inc. (NASDAQ: ALT) by 48.6% in

GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical

Shares of Altimmune, Inc. (NASDAQ: ALT - Get Free Report) have been given a consensus rating of "Mod

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory ba

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines,

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemviduti

Dimensional Fund Advisors LP raised its holdings in Altimmune, Inc. (NASDAQ: ALT) by 268.7% during t

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA tria

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.12) per share which beat the analyst consens

Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2

Altimmune reports positive Phase 2 RECLAIM trial data for pemvidutide in AUD and plans to request an

Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heav

Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperf

The data are being presented today and Friday in poster sessions, including a late-breaking poster p

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy a

Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and

Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in "

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.18) per share which beat the analyst consens

Altimmune shares fall after a $225 million offering raises dilution concerns while funding key late-

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl

Altimmune intends to use the net proceeds from this proposed offering to fund its upcoming Phase 3 t

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy a

B. Riley Securities analyst William Woods maintains Altimmune (NASDAQ:ALT) with a Buy and lowers

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.27) per share. This is a 18.18 percent incre

Altimmune shares are tumbling on Wednesday following the company's announcement of a $75 million